VIVA BIOTECH HOLDINGS |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.56 HKD | 0.00% |
|
+34.94% | -46.67% |
| 03-28 | Viva Biotech Holdings Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 01-18 | Viva Biotech Holdings Appoints WANG Stephen Hui as Non-Executive Director | CI |
| Sales 2021 | 2.1B 290M 2.27B 397M | Sales 2022 | 2.38B 328M 2.57B 449M | Capitalization | 2.96B 409M 3.2B 559M |
|---|---|---|---|---|---|
| Net income 2021 | 288M 39.75M 311M 54.34M | Net income 2022 | -528M -72.87M -570M -99.62M | EV / Sales 2021 | 4.38 x |
| Net Debt 2021 | 1.85B 256M 2B 350M | Net Debt 2022 | 2.14B 296M 2.32B 405M | EV / Sales 2022 | 2.15 x |
| P/E ratio 2021 |
46.5
x | P/E ratio 2022 |
-5.52
x | Employees | 2,077 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 63.36% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 week | +34.94% | ||
| Current month | +3.70% | ||
| 1 month | +9.80% | ||
| 3 months | -20.00% | ||
| 6 months | -56.92% | ||
| Current year | -46.67% |
1 week
0.41
0.60
1 month
0.410.60
Current year
0.411.05
1 year
0.412.00
3 years
0.4111.64
5 years
0.4111.64
10 years
0.4111.64
| Managers | Title | Age | Since |
|---|---|---|---|
Ying Wu
FOU | Founder | 60 | 08-08-26 |
Chen Mao
CEO | Chief Executive Officer | 61 | 08-08-26 |
Wei Xiong
DFI | Director of Finance/CFO | 41 | 11-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Xiang Rong Li
BRD | Director/Board Member | 51 | 17-12-31 |
| - | - | ||
Hai Guang Wang
BRD | Director/Board Member | 60 | 17-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.28% | 4 M€ | -27.92% | ||
| 0.00% | 4 M€ | -4.41% | - | |
| 0.00% | 117 M€ | +1.11% | - | |
| 0.00% | 34 M€ | +2.14% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 0.56 | 0.00% | 5,410,268 |
| 24-04-25 | 0.56 | +17.89% | 11,217,000 |
| 24-04-24 | 0.475 | +9.20% | 2,803,000 |
| 24-04-23 | 0.435 | +2.35% | 3,213,000 |
| 24-04-22 | 0.425 | +2.41% | 1,960,000 |
Delayed Quote Hong Kong S.E., April 26, 2024 at 04:08 am
More quotes
VIVA Biotech Holdings is a China-based investment holding company. The Company is principally engaged in the provision of the structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide for their pre-clinical stage innovative drug development. The Companyâs core technologies include structure-based drug discovery (SBDD) platform, fragment-based drug discovery (FBDD) platform, affinity selection mass spectrometry (ASMS) screening platform and membrane protein targeted drug discovery platform. The Company operates its businesses mainly in the United States, China, Europe and other regions.
Sector
Pharmaceuticals
Calendar
2024-06-25
- Annual General Meeting
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -46.67% | 153M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- 1873 Stock
